The state of Massachusetts currently has 533 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Care Transition Intervention for Hospitalized Patients With Advanced Cancer
NCT05142345
Recruiting
This study is examining whether a care transition intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consisting of a supportive care-focused video visit with an oncology nurse practitioner (NP) within three business days of hospital discharge, may improve post-discharge transitions of care for recently hospitalized patients with advanced cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/10/2022
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Cancer, Follow-Up Care, Consultation, Remote, Advanced Cancer
Register for Updates
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Solid Tumors, GI Cancer
Register for Updates
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
NCT03945721
Recruiting
This research study involves Niraparib as a possible treatment for triple negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/27/2021
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Triple Negative Breast Cancer, Residual Disease
Register for Updates
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
NCT04859777
Recruiting
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors. The study will be conducted in 3 parts: Part A: MPT-0118 dose-escalation Part B: MPT-0118 dose-escalation in combination with pembrolizumab Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
09/15/2021
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
Register for Updates
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
NCT03891615
Recruiting
This research study is studying a combination of drugs as a possible treatment for EGFR-Mutated Advanced Lung Cancer. The names of the study drugs involved in this study are Niraparib and Osimertinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/14/2020
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Lung Cancer
Register for Updates